Category

Articles about Bilastine

Congreso bilastina

Bilastine symposium at the EAACI 2019 congress

By | Articles about Bilastine

On the occasion of the celebration of the 38th congress of the European Academy of Allergy and Clinical Immunology (EAACI), which will take place between 1 and 5 June in Lisbon, Faes Farma announces the holding of an important symposium specifically aimed at its antihistamine. own research, bilastine.

This meeting is scheduled for June 2 at 5:30 pm in Hall 5 of the conference venue.

With the title “BILASTINE: A lifetime companion. Value every moment of your life. “, counts as chairman with Prof. Martin Church (UK) and three specialist speakers of international prestige.

The first presentation will be made by Dr. Ralph Mösges (Germany) and will deal with the on-off relationship of patients with their treatments of allergic rhinitis.

The second presentation will be offered by Dr. Marysia Recto (Philippines) and will analyze the needs not covered in patients with urticaria.

Finally, Dr. Zoltán Nóvak (Hungary) will show the need for antihistamine treatments not to affect the life and daily activities of pediatric allergic patients.

You are cordially invited.

You can access the audiovisual contents of other editions in this link.

Relevancia clínica interacción medicamentos y alimentos

Lack of clinical relevance of bilastine-food pharmacokinetic interaction assessed by inhibition of histamine-induced wheal and flare response in healthy volunteers

By | Articles about Bilastine

Jimena Coimbra, Cristina Campo, Luis Labeaga, Montserrat Puntes, Ignasi Gich, Joan Martínez, Rosa Antonijoan.

The main objective of this study was to compare the efficacy of bilastine 20mg administered orally, under fasting and fed conditions, in the reduction of histamine-induced skin reactivity (wheal and flare response) in healthy volunteers, taking into account the first treatment day (Day1) and the steady state (Day4). The final aim of this study was to assess the clinical relevance of this food-drug interaction.
As a conclusión of the study, the pharmacokinetic interaction of bilastine with food does not imply a significant reduction of its antihistamine efficacy, and the interaction of bilastine with food lacks clinical relevance since no significant pharmacodynamic interaction was observed.

This document is only available for registered healthcare professionals

Login

Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study

By | Articles about Bilastine

Esther Serra, Cristina Campo, Zoltan Novák, Bernardetta Majorek-Olechowska, G Pulka, Aintzane García-Bea & Luis Labeaga (2019)

Journal of Dermatological Treatment

An exploratory, international and multicenter study to evaluate the efficacy of bilastine in the relief of pruritus associated with urticaria and other skin diseases was performed in patients diagnosed of Chronic Spontaneous Urticaria (CSU), eczema/dermatitis, prurigo or cutaneous pruritus.

The first 2 weeks, they were treated with bilastine 20 mg daily. The daily pruritus severity score was assessed. Responders patients stayed on this treatment for the remaining 6 weeks while non-responders were updosed to 40 mg.

The mean change in weekly pruritus severity score from baseline to week 8 was -1.63 ± 0.77 for all patients (p<0.001). The mean change per group was: CSU (-2.1 ± 0.44), cutaneous pruritus (-1.66 ± 0.63), eczema/dermatitis (-1.36 ± 0.79) and prurigo (-1.30 ± 0.92) (all p-values <0.001).

Bilastine at 20 mg and 40 mg showed an excellent profile for both efficacy and safety in reducing pruritus in patients with CSU and other skin disorders.

This document is only available for registered healthcare professionals

Login
Antihistamínicos H1

Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties.

By | Articles about Bilastine
Kawauchi H, Yanai K, Wang DY, Itahashi K, Okubo K.

Antihistamines targeting the histamine H₁ receptor play an important role in improving and maintaining the quality of life of patients with allergic rhinitis. For more effective and safer use of second-generation drugs, which are recommended by various guidelines, a classification based on their detailed characteristics is necessary. Antihistamines for first-line therapy should not have central depressant/sedative activities.
Among the non-sedating group, fexofenadine and bilastine are classified into “non-brain-penetrating antihistamines”.
This review summarizes that the non-brain-penetrating antihistamines should be chosen for the first-line therapy of mild allergic rhinitis.

This document is only available for registered healthcare professionals

Login

The long duration of action of the second generation antihistamine bilastine coincides with its long residence time at the histamine H1 receptor

By | Articles about Bilastine
Bosma R, van den Bor J, Vischer HF, Labeaga L, Leurs R

Bilastine shows a long drug-target residence time at the H1 receptor (73 ± 5 min) and this results in a prolonged H1 receptor antagonism in vitro (Ca2+ mobilization in Fluo-4 loaded HeLa cells), following a washout of unbound antagonist. Hence, the long residence time of bilastine can explain the observed long duration of drug action in vivo.

This document is only available for registered healthcare professionals

Login
Antihistamínico novel

Bilastine – A Novel Antihistamine for Allergic Rhinitis and Chronic Spontaneous Urticaria

By | Articles about Bilastine
Kraft JN, Sussman GL

Bilastine has a proven, long-term safety record with use by over 71 million patients in over 104 countries. This novel, second generation antihistamine is non-sedating due to the fact that it does not cross the blood brain barrier. As well, bilastine is not metabolized and does not interact with CYP450.

This document is only available for registered healthcare professionals

Login
F1 simulador

Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients

By | Articles about Bilastine
Demonte A, Guanti MB, Liberati S, Biffi A, Fernando F, Fainello M, Pepe P

This study is the first done in patients with allergic rhinitis and/or chronic urticaria using a F1-high speed simulator-driving test evaluating subjects’ performance under bilastine treatment.

This document is only available for registered healthcare professionals

Login
Estudio de bilastina en pacientes japoneses

One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases

By | Articles about Bilastine
Yagami A, Furue M, Togawa M, Saito A, Hide M.

A number of second-generation non-sedating antihistamines are used in clinical practices over the world. However, long-term safety and efficacy have not been proved high level evidence based medicine. 
In conclusion, long-term treatment with bilastine 20 mg once daily for 52 weeks is safe and well tolerated in Japanese patients with hronic spontaneous urticaria (CSU) or pruritus associated with skin diseases. Bilastine improved disease symptoms of both conditions early in treatment, and the efficacy was maintained throughout the treatment.

This document is only available for registered healthcare professionals

Login
bilastina en pacientes japoneses

Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects

By | Articles about Bilastine
Togawa M, Yamaya H, Rodríguez M, Nagashima H.

Bilastine exhibits similar single- and multiple-dose pharmacokinetic and pharmacodynamic characteristics in healthy Japanese subjects compared with those observed in Caucasian subjects in previous studies.

This document is only available for registered healthcare professionals

Login

La información que está a punto de visualizar está dirigida únicamente a los profesionales sanitarios aptos para prescribir o dispensar medicamentos. La correcta utilización de su contenido requiere de formación como profesional sanitario.

Debe hacer clic en Aceptar para confirmar que es usted profesional de la salud y continuar con la navegación.

ACEPTAR